Improved All Cause and Cardiovascular Mortality and Morbidity by Empagliflozin: Too Good to Be True!

ISSN Print: 2160-5831
ISSN Online: 2160-5858
www.scirp.net/journal/jdm
E-mail: [email protected]

Citations

"Improved All Cause and Cardiovascular Mortality and Morbidity by Empagliflozin: Too Good to Be True!"
written by Udaya M. Kabadi,
published by Journal of Diabetes Mellitus, Vol.6 No.2, 2016

has been cited by the following article(s):

[1]	ADVERSE EFFECTS OF SGLT2 INHIBITORS: A SYSTEMIC REVIEW
	2023

[2]	SGLT2 Inhibitors: Far Too Many Cautions and Alerts and Limited Efficacy
	2018

[3]	CARDIOVASCULAR OUTCOME TRIALS IN TYPE 2 DIABETES: RELIABLE OR BIASED!
	WORLD JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH, 2017